Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies (pathogenic B cells) while sparing normal B cells. Our technology, in combination with our proprietary Cabaletta Approach for selective B cell Ablation platform, called our CABA platform, has applicability across more than two dozen B cell-mediated autoimmune diseases. Using our CABA platform, we have discovered and developed four product candidates, including our lead product candidate, in development to treat patients with mucosal pemphigus vulgaris, or mPV. We hold multiple agreements with Penn to develop CAAR T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and engineered T cell therapy and our Penn collaboration to rapidly discover and develop our portfolio of CAAR T product candidates.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
09/15/2020 at 4:30 PM EDT
09/14/2020 at 3:00 PM EDT
08/12/2020 at 11:30 AM EDT